PE ratio relative to earnings growth — is the valuation justified?
| Symbol | Company | PEG | P/E | Growth | vs ABBV |
|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | 0.12 | 17.7 | 149.5% | — |
| LLY | Eli Lilly and Company | 1.48 | 40.8 | 27.5% | — |
| MRK | Merck & Co., Inc. | 1.73 | 36.7 | 21.2% | — |
| BMY | Bristol-Myers Squibb Company | 2.75 | 14.4 | 5.2% | — |
| AMGN | Amgen Inc. | 9.13 | 26.8 | 2.9% | — |